Similar articles

• Re: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.

  Joffe S. Joffe S. J Natl Cancer Inst. 2013 Jul 3;105(13):993. doi: 10.1093/jnci/djt125. Epub 2013 May 30. J Natl Cancer Inst. 2013. PMID: 23723419 No abstract available.
• Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.

  Gupta S, Hunsberger S, Boerner SA, Rubinstein L, Royds R, Ivy P, LoRusso P. Gupta S, et al. J Natl Cancer Inst. 2012 Dec 19;104(24):1860-6. doi: 10.1093/jnci/djs439. Epub 2012 Nov 19. J Natl Cancer Inst. 2012. PMID: 23169991
• Response.

  Hunsberger S, Rubinstein L, Boerner SA, LoRusso P. Hunsberger S, et al. J Natl Cancer Inst. 2013 Jul 3;105(13):993-4. doi: 10.1093/jnci/djt126. Epub 2013 May 30. J Natl Cancer Inst. 2013. PMID: 23723418 Free PMC article. No abstract available.
• Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.

  Mandrekar SJ. Mandrekar SJ. Am Soc Clin Oncol Educ Book. 2014:e107-10. doi: 10.14694/EdBook_AM.2014.34.e107. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857087 Review.
• Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.

  Sachs JR, Mayawala K, Gadamsetty S, Kang SP, de Alwis DP. Sachs JR, et al. Clin Cancer Res. 2016 Mar 15;22(6):1318-24. doi: 10.1158/1078-0432.CCR-15-1295. Epub 2015 Nov 23. Clin Cancer Res. 2016. PMID: 26597302 Review.